InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.04
(
-0.41%
)
Bitcoin
63,241.46
(
-1.56%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

CruelShoes

Send PM Follow Ignore
Followers 0
Posts 27
Boards Moderated 0
Alias Born 07/18/2006

CruelShoes

Re: None

Wednesday, 01/10/2007 9:09:59 AM

Wednesday, January 10, 2007 9:09:59 AM

Post# of 4764
Do any of these news stories include the PFS numbers or any of the secondary endpoint numbers? I haven't seen it. Please don't tell me we have to wait until ASCO to get the numbers.

"The CRYSTAL trial will evaluate the impact of adding cetuximab 250 mg/m^2/week to FOLFIRI in approximately 1100 patients with previously untreated EGFR-positive metastatic CRC. Progression-free survival is the primary endpoint, with OS, RR, response duration, safety, and quality of life being secondary endpoints."
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up